Your browser is no longer supported. Please, upgrade your browser.
Settings
SRPT Sarepta Therapeutics, Inc. daily Stock Chart
SRPT [NASD]
Sarepta Therapeutics, Inc.
Index- P/E- EPS (ttm)-5.28 Insider Own0.40% Shs Outstand53.82M Perf Week0.00%
Market Cap1.76B Forward P/E- EPS next Y-1.40 Insider Trans-45.22% Shs Float50.96M Perf Month-23.46%
Income-243.50M PEG- EPS next Q-0.91 Inst Own77.50% Short Float19.69% Perf Quarter17.74%
Sales1.30M P/S1352.12 EPS this Y-53.40% Inst Trans21.68% Short Ratio2.29 Perf Half Y68.26%
Book/sh8.47 P/B3.86 EPS next Y70.20% ROA-82.60% Target Price71.50 Perf Year-11.78%
Cash/sh7.34 P/C4.45 EPS next 5Y-0.20% ROE-113.30% 52W Range8.00 - 63.73 Perf YTD-15.34%
Dividend- P/FCF- EPS past 5Y- ROI-103.00% 52W High-48.75% Beta1.94
Dividend %- Quick Ratio6.70 Sales past 5Y-46.80% Gross Margin- 52W Low308.25% ATR2.31
Employees270 Current Ratio6.70 Sales Q/Q- Oper. Margin- RSI (14)33.01 Volatility5.61% 6.50%
OptionableYes Debt/Eq0.05 EPS Q/Q5.90% Profit Margin- Rel Volume0.46 Prev Close34.49
ShortableYes LT Debt/Eq0.02 EarningsOct 27 BMO Payout- Avg Volume4.37M Price32.66
Recom1.90 SMA20-10.70% SMA50-25.95% SMA20016.76% Volume2,012,267 Change-5.31%
Oct-28-16Reiterated RBC Capital Mkts Outperform $108 → $106
Oct-27-16Initiated Morgan Stanley Equal-Weight $53
Oct-18-16Initiated Credit Suisse Outperform $68
Oct-10-16Reiterated Wedbush Outperform $66 → $72
Sep-28-16Reiterated RBC Capital Mkts Outperform $83 → $108
Sep-20-16Reiterated Needham Buy $47 → $81
Sep-19-16Upgrade RBC Capital Mkts Sector Perform → Outperform $5 → $83
Sep-19-16Upgrade Jefferies Underperform → Hold
Sep-19-16Reiterated Robert W. Baird Outperform $23 → $102
Jul-22-16Reiterated Needham Buy $20 → $26
Jun-09-16Upgrade Piper Jaffray Underweight → Neutral
Jun-07-16Upgrade Wedbush Neutral → Outperform $36
Jun-01-16Reiterated Wedbush Outperform $14 → $23
May-03-16Downgrade Leerink Partners Mkt Perform → Underperform
Apr-29-16Downgrade Jefferies Hold → Underperform
Apr-26-16Reiterated RBC Capital Mkts Sector Perform $7.50 → $5
Apr-26-16Reiterated Needham Buy $53 → $20
Apr-26-16Downgrade Sun Trust Rbsn Humphrey Neutral → Reduce
Apr-26-16Downgrade Piper Jaffray Neutral → Underweight
Apr-22-16Reiterated RBC Capital Mkts Sector Perform $14 → $7.50
Dec-09-16 03:02PM  Should You Be Concerned That Smart Money Is Fleeing ALLETE Inc (ALE)? at Insider Monkey -5.31%
Dec-07-16 06:49PM  PTC Therapeutics, Inc. in 3 Charts at Motley Fool
02:46PM  Dow, S&P 500 Trade at Session Highs in Broad Wall Street Rally
04:03AM  Hedge Funds Are Crazy About Sarepta Therapeutics Inc (SRPT) at Insider Monkey
Dec-05-16 09:23AM  Is This Why Sarepta Therapeutics Fell 14.5% in November? at Motley Fool
Dec-02-16 03:24PM  Sarepta Drug Gets UnitedHealth Coverage (SRPT, UNH) at Investopedia
11:33AM  New Aetna Clinical Policy Bulletin Details 'Medical Necessity' Of Sarepta's Exondys 51
Dec-01-16 11:47AM  5 Medical Tech Stocks You Should Be Investing In at Insider Monkey -6.01%
11:05AM  Sarepta: UnitedHealth Induced Selloff a Buying Opportunity? at Barrons.com
Nov-30-16 06:00PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire -6.70%
04:10PM  The 21st Century Cures Act Will Not Fix The FDA at Forbes
Nov-29-16 01:55PM  Sarepta Therapeutics: A Mistake to Underestimate Its Sales, Baird Says at Barrons.com
Nov-21-16 02:19PM  Aetna Still Undecided On Coverage For Sarepta's Highly Debated Muscular Dystrophy Treatment
Nov-17-16 01:04PM  SAREPTA THERAPEUTICS, INC. Financials
09:28AM  10 biotech companies ripe for a buyout, courtesy of Donald Trump at MarketWatch
08:56AM  3 Stocks to Add to Your Portfolio as Biotech M&A Hopes Rise
Nov-14-16 12:10PM  Why PTC Therapeutics Is Soaring Again at Motley Fool
07:58AM  How Donald Trump May Impact The FDA at Forbes
Nov-11-16 01:25PM  Why not everyone is buying the market hype surrounding Sareptas Duchenne drug at bizjournals.com
10:30AM  3 Reasons 2017 Launch Expectations For Sarepta's EXONDYS 51 Are 'Too High'
08:10AM  PTC Therapeutics Duchenne Drug Wins Extended European Approval
01:00AM  Trump presidency could prove a salve for pharma merger deals Reuters
Nov-08-16 05:40PM  Why Cempra Inc Fell Over the Last 2 Days at Motley Fool
12:53PM  Big Bet on Sarepta Therapeutics Inc (SRPT) Lifts Perceptive Advisors Q3 Returns; See How Other Investments Performed at Insider Monkey
Nov-07-16 08:33AM  SAREPTA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
Nov-04-16 08:30AM  Sarepta Therapeutics to Present Company Overview at the Credit Suisse 25th Annual Healthcare Conference Business Wire +5.52%
Nov-01-16 01:13PM  4 Stocks I'd Avoid at All Costs at Motley Fool
Oct-31-16 05:30PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Oct-29-16 08:16AM  3 Stocks to Avoid in Biotech at Motley Fool
Oct-28-16 12:56PM  Sarepta Therapeutics Inc. (SRPT) Stock: Jason Karp Is A Shareholder Again And Has A Larger Position Than Ever at Insider Monkey
10:04AM  Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : SRPT-US : October 28, 2016
09:35AM  Sarepta Therapeutics (SRPT) Incurs Narrower Y/Y Loss in Q3
Oct-27-16 02:32PM  Why Sarepta is Sinking at Barrons.com -8.37%
01:24PM  Edited Transcript of SRPT earnings conference call or presentation 27-Oct-16 12:00pm GMT
08:41AM  Sarepta Therapeutics reports 3Q loss
08:00AM  Sarepta Therapeutics Inc Earnings Call scheduled for 8:00 am ET today
07:28AM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
07:07AM  Q3 2016 Sarepta Therapeutics Inc Earnings Release - Before Market Open
07:00AM  Sarepta Therapeutics Announces Third Quarter 2016 Financial Results and Recent Corporate Developments Business Wire
06:24AM  Coverage initiated on Sarepta Therapeutics by Morgan Stanley
Oct-25-16 01:34PM  Sarepta: 'Setting Aside the Controversy Around the Questionable Data' at Barrons.com
Oct-24-16 08:30AM  Sarepta Therapeutics to Announce Third Quarter 2016 Financial Results and Recent Corporate Developments on October 27, 2016 Business Wire
Oct-21-16 08:00AM  Best And Worst Biotech ETFs Of 2016 Tell A Tale About This Industry
Oct-20-16 10:45AM  Trader Be Nimble, Trader Be Quick
Oct-18-16 04:43PM  Sarepta Muscular Dystrophy Drug Interrupts 5-Day Biotech Slump
11:20AM  Sarepta Therapeutics: If You Approve It They Will Come at Barrons.com
08:59AM  PTC Therapeutics Falls on FDA Denial of DMD Drug Appeal
Oct-17-16 05:21PM  Sarepta Therapeutics' Greatest Threat: Anthem? at Motley Fool -6.39%
Oct-13-16 11:39AM  Pardon Me, but I Have a Few Things to Say... Seattle Genetics, Biomarin, Sarepta, TG Therapeutics
Oct-12-16 01:22PM  Todays Trending Stocks: Sarepta, Humana, HTG Molecular Diagnostics, and More at Insider Monkey
08:39AM  Biotech Stock Roundup: Alnylam Slumps on Revusiran Update, TESARO Impresses at ESMO
Oct-11-16 03:41PM  Why Sarepta Therapeutics Skyrocketed 131% in September at Motley Fool -6.64%
11:27AM  Health insurers split on coverage of Sareptas Duchenne drug at bizjournals.com
Oct-10-16 04:57PM  Sarepta Tumbles After Anthems Refusal (SRPT, ANTM) at Investopedia
11:00AM  Better Buy: Alnylam Pharmaceuticals, Inc. vs. Sarepta Therapeutics, Inc. at Motley Fool
Oct-08-16 02:46PM  New Anthem policy will cost DMD patients $300,000 or more at MarketWatch
Oct-07-16 02:56PM  Anthem says will not cover Sarepta's approved Duchenne drug -6.24%
01:05PM  Why Sarepta Therapeutics, Ralph Lauren, Fifth Third Bancorp, and Two Other Stocks Are in Spotlight on Friday at Insider Monkey
12:36PM  Anthem won't cover first FDA-approved Duchenne drug Reuters
12:10PM  Sarepta Therapeutics (SRPT) Stock Drops, Anthem Says DMD Drug 'Not Medically Necessary'
11:23AM  Sarepta stock down 4.8% after Anthem signals it won't cover new DMD drug at MarketWatch
Oct-06-16 12:08PM  CureDuchenne to Host SareptAssist Webinar on October 11 to Provide an Overview of Sareptas Patient Support Program for Duchenne Families Business Wire
Oct-05-16 03:16PM  Sareptas Exondys 51 Drug May Cost $300,000 (SRPT) at Investopedia
01:27PM  Sarepta's Deal With Summit Could Be More About European Eteplirsen Approval Expectations
11:11AM  Ignore Market Jitters, Let Price Action Be the Guide
10:06AM  Sarepta/Summit Ink Deal for Utrophin Modulator DMD Drugs
09:29AM  Biotech Stock Roundup: Summit Soars on Sarepta Deal, Regeneron Presents Data
09:15AM  Blog Coverage Sarepta Announces Collaboration with Summit Therapeutics Accesswire
08:57AM  Blog Coverage Sarepta Announces Collaboration with Summit Therapeutics
Oct-04-16 06:00PM  Sarepta Inks Key DMD Deal (SRPT) at Investopedia
04:09PM  Sarepta may be the real winner from partnership that lifted Summit Therapeutics stock 50% at MarketWatch
02:23PM  Trending Tickers: SDRL, P, SMMT, SRPT
02:21PM  Sarepta Therapeutics (SRPT) Stock Up on Summit Deal, RBC Bullish
12:12PM  Analyst: Sarepta removes potential competitive threat with $562M deal at bizjournals.com
11:34AM  Why Sarepta's Licensing Deal Makes This Drug Maker An "Even More Attractive M&A Candidate" at Barrons.com
11:17AM  Sarepta Therapeutics (SRPT) Stock Gains on Summit Licensing Agreement
11:00AM  DMD Deal With Summit Is 'Low Risk, High Reward' For Sarepta
10:35AM  Summit Therapeutics Skyrockets on Sarepta Deal
09:46AM  Early Movers: Darden Lifts Earnings Forecast; Trinity Biotech Plunges, Yanks FDA Applicaiton at Barrons.com
09:22AM  Summit Therapeutics (SMMT) Stock Spikes on Sarepta Licensing Deal
08:37AM  Sarepta Wins Exclusive License, Collaboration Deal for European Rights To Summit's DMD Drug
07:58AM  Summit Therapeutics stock surges 50% on news of licensing deal with Sarepta at MarketWatch
07:29AM  Summit and Sarepta to collaborate on muscular dystrophy drug
07:07AM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E
07:00AM  Sarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement for European Rights to Summits Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy GlobeNewswire
Oct-03-16 08:39AM  6 Best Performing Drug Stocks of September
Oct-02-16 10:05AM  Top 6 Biopharma Gainers of the Past Week at 24/7 Wall St.
09:57AM  Is Sarepta Therapeutics Still a Risky Bet? at Motley Fool
Oct-01-16 09:00AM  'Mad Money' Lightning Round: Buy, Buy, Buy Home Depot
Sep-30-16 07:21PM  Cramer: We've missed the big move on Sarepta Therapeutics at CNBC
04:16PM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Other Events
01:28PM  Biotech stocks have plenty of catalysts around the corner at MarketWatch
12:56PM  Kite, Anavex, G.W. Pharma Help Revive Biotech Sector Chemistry
12:49PM  Shark Bites: Market Responds With 'Deutsche Who?'
10:54AM  One Biotech Crashes, the Other Skyrockets -- Here's Why at Motley Fool
10:28AM  The Crazy Backstory Around Sarepta Therapeutics' Game-Changing Drug Approval at Motley Fool
09:13AM  5 Top Performing Stocks of the Best ETF of Q3
Sep-29-16 12:40PM  Catabasis Skyrockets on Sarepta Partnership
11:34AM  Sarepta announces Duchenne research partnership with Cambridge's Catabasis at bizjournals.com
08:00AM  Catabasis Pharmaceuticals and Sarepta Therapeutics Announce a Joint Research Collaboration in Duchenne Muscular Dystrophy Business Wire
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. The company's lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development for the treatment of individuals with Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease caused by the absence of dystrophin. It is also developing exon-skipping drugs for the treatment of DMD; and therapeutic candidates for the treatment of infectious diseases, such as influenza, Marburg, and Ebola. The company has a strategic alliance with Charley's Fund, Inc. to support the development of product candidates using its proprietary exon-skipping technologies; a license agreement with the University of Western Australia for the use of antisense sequences in the treatment of DMD; and a research collaboration agreement with Catabasis Pharmaceuticals, Inc to explore a combination drug treatment approach for DMD. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kaye Edward M. MDPresident, CEO & CMONov 09Option Exercise8.283,00024,84075,635Nov 10 08:19 AM
Howton David TSVP, General CounselNov 09Option Exercise23.851,00023,85022,453Nov 10 08:27 AM
Mahatme SandeshSenior Vice President, CFONov 09Option Exercise23.851,00023,85032,532Nov 10 08:26 AM
Ruff ShamimSVP, Regulatory Affairs & QualNov 08Option Exercise26.241,00026,24021,239Nov 10 08:20 AM
Mahatme SandeshSenior Vice President, CFOOct 17Option Exercise13.9030,000417,00061,532Oct 19 04:22 PM
Mahatme SandeshSenior Vice President, CFOOct 17Sale50.0830,0001,502,50231,532Oct 19 04:22 PM
Kaye Edward M. MDPresident, CEO & CMOSep 22Option Exercise8.2840,179332,682117,162Sep 26 04:23 PM
Howton David TSVP, General CounselSep 22Option Exercise13.907,00097,30028,453Sep 26 04:19 PM
Ruff ShamimSVP, Regulatory Affairs & QualSep 22Option Exercise13.907,311101,62327,550Sep 30 09:58 PM
Ruff ShamimSVP, Regulatory Affairs & QualSep 22Sale60.007,311438,66020,239Sep 30 09:58 PM
Kaye Edward M. MDPresident, CEO & CMOSep 22Sale60.0040,1792,410,74076,983Sep 26 04:23 PM
Howton David TSVP, General CounselSep 22Sale60.007,000420,00021,453Sep 26 04:19 PM
Howton David TSVP, General CounselSep 19Option Exercise13.908,000111,20011,168Sep 21 09:28 PM
Kaye Edward M. MDPresident, CEO & CMOSep 19Option Exercise6.9424,352168,94189,983Sep 21 09:29 PM
Aphale JayantVP, Technical OperationsSep 19Option Exercise4.6235,000161,70036,490Sep 21 09:31 PM
Aphale JayantVP, Technical OperationsSep 19Sale50.0035,0001,750,00011,490Sep 21 09:31 PM
Kaye Edward M. MDPresident, CEO & CMOSep 19Sale50.0024,3521,217,60076,983Sep 21 09:29 PM
Howton David TSVP, General CounselSep 19Sale50.009,304465,2003,168Sep 21 09:28 PM
Kaye Edward M. MDSVP Interim CEO & CMOSep 14Sale30.0024,557736,71076,983Sep 16 04:04 PM
BEHRENS M KATHLEENDirectorMar 16Buy14.5410,000145,43321,855Mar 16 08:15 PM
BEHRENS M KATHLEENDirectorMar 14Buy16.5465,0001,075,276112,166Mar 16 08:15 PM
Barry RichardDirectorMar 14Buy15.6675,0001,174,1853,241,014Mar 16 08:09 PM